Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.

Description

The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.

API Access

Has API No 

API Access

Has API No 

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Customer Support

Business Hours No 
Live Rep (24/7) No 
Online Support Yes 

Types of Training

Training Docs Yes 
Webinars No 
Live Training (Online) Yes 
In Person No 

Types of Training

Training Docs No 
Webinars No 
Live Training (Online) No 
In Person No 

Vendor Details

Company Name

BenevolentAI

Founded

2013

Country

Luxembourg

Website

www.benevolent.com

Vendor Details

Company Name

Gritstone bio

Founded

2015

Country

United States

Website

gritstonebio.com/scientific-platform/

Product Features

Alternatives

Alternatives

MIStar Reviews

MIStar

Apollo Medical Imaging Technology
MIRIO Reviews

MIRIO

DEEPLINK MEDICAL